Harnessing Akkermansia muciniphila Membrane Coating for Probiotic Therapy in Inflammatory Bowel Disease

Area of Science:

• Microbiology
• Gastroenterology
• Biotechnology

Background:

• Inflammatory bowel diseases (IBD) involve inflammation, oxidative stress, and gut barrier dysfunction.
• Current IBD treatments have limitations, including side effects and suboptimal efficacy.
• Akkermansia muciniphila (AKK) bacterial membrane components show therapeutic potential for IBD.

Purpose of the Study:

• To develop a novel probiotic oral delivery system for IBD treatment.
• To engineer nanocoated probiotics using AKK bacterial membranes (AKM) and astaxanthin (AST).
• To evaluate the efficacy and safety of AKM-AST@EcN for IBD therapy.

Main Methods:

• Engineered nanocoated probiotics using Escherichia coli Nissle 1917 (EcN) as a delivery vehicle.
• Incorporated self-assembled AKK bacterial membrane and astaxanthin (AST) to form a protective coating.
• Assessed gastrointestinal (GI) tract tolerance and bioactivity of the engineered probiotics.

Main Results:

• The developed AKM-AST@EcN nanocoated probiotics demonstrated excellent GI tract tolerance.
• The nanocoating provided a robust biological barrier, enhancing probiotic stability and function.
• Engineered probiotics exhibited significant bioactivity relevant to IBD treatment.

Conclusions:

• AKM-AST@EcN represents a promising therapeutic strategy for managing inflammatory bowel diseases.
• This approach offers a novel method for developing effective probiotic oral delivery systems.
• The study highlights the potential of bacterial membrane components in advanced therapeutic applications.